April 4, 2019
|
April 8, 2019
|
December 5, 2022
|
July 1, 2019
|
December 2022 (Final data collection date for primary outcome measure)
|
Depression Severity: clinician-rated [ Time Frame: week 6 ] Hamilton Rating Scale for Depression (HAMD-17)
|
Same as current
|
|
- Depression Severity: clinician-rated [ Time Frame: week 1 ]
Hamilton Rating Scale for Depression (HAMD-17)
- Depression Severity: clinician-rated [ Time Frame: week 3 ]
Hamilton Rating Scale for Depression (HAMD-17)
- Depression Severity: clinician-rated [ Time Frame: week 12 ]
Hamilton Rating Scale for Depression (HAMD-17)
- Depression Severity: patient-rated [ Time Frame: week 1 ]
Beck Depression Inventory II (BDI-II)
- Depression Severity: patient-rated [ Time Frame: week 3 ]
Beck Depression Inventory II (BDI-II)
- Depression Severity: patient-rated [ Time Frame: week 6 ]
Beck Depression Inventory II (BDI-II)
- Depression Severity: patient-rated [ Time Frame: week 12 ]
Beck Depression Inventory II (BDI-II)
- Global improvement: clinician-rated [ Time Frame: week 1 ]
Clinical Global Impression Scale (CGI)
- Global improvement: clinician-rated [ Time Frame: week 3 ]
Clinical Global Impression Scale (CGI)
- Global improvement: clinician-rated [ Time Frame: week 6 ]
Clinical Global Impression Scale (CGI)
- Global improvement: clinician-rated [ Time Frame: week 12 ]
Clinical Global Impression Scale (CGI)
- Global Functioning: clinician-rated [ Time Frame: week 1 ]
Global Assessment of Functioning Scale (GAF)
- Global Functioning: clinician-rated [ Time Frame: week 3 ]
Global Assessment of Functioning Scale (GAF)
- Global Functioning: clinician-rated [ Time Frame: week 6 ]
Global Assessment of Functioning Scale (GAF)
- Global Functioning: clinician-rated [ Time Frame: week 12 ]
Global Assessment of Functioning Scale (GAF)
- Fatigue: patient-rated [ Time Frame: week 1 ]
Multidimensional Fatigue Inventory (MFI)
- Fatigue: patient-rated [ Time Frame: week 3 ]
Multidimensional Fatigue Inventory (MFI)
- Fatigue: patient-rated [ Time Frame: week 6 ]
Multidimensional Fatigue Inventory (MFI)
- Fatigue: patient-rated [ Time Frame: week 12 ]
Multidimensional Fatigue Inventory (MFI)
- Stress: patient-rated [ Time Frame: week 1 ]
Perceived Stress-Scale (PSS)
- Stress: patient-rated [ Time Frame: week 3 ]
Perceived Stress-Scale (PSS)
- Stress: patient-rated [ Time Frame: week 6 ]
Perceived Stress-Scale (PSS)
- Stress: patient-rated [ Time Frame: week 12 ]
Perceived Stress-Scale (PSS)
- Quality of Life: patient-rated [ Time Frame: week 1 ]
Short Form Health Survey (SF-12)
- Quality of Life: patient-rated [ Time Frame: week 3 ]
Short Form Health Survey (SF-12)
- Quality of Life: patient-rated [ Time Frame: week 6 ]
Short Form Health Survey (SF-12)
- Quality of Life: patient-rated [ Time Frame: week 12 ]
Short Form Health Survey (SF-12)
- Biomarkers: interleukin 2 [ Time Frame: week 1 ]
IL-2
- Biomarkers: interleukin 2 [ Time Frame: week 3 ]
IL-2
- Biomarkers: interleukin 2 [ Time Frame: week 6 ]
IL-2
- Biomarkers: interleukin 2 [ Time Frame: week 12 ]
IL-2
- Biomarkers: interleukin 6 [ Time Frame: week 1 ]
IL-6
- Biomarkers: interleukin 6 [ Time Frame: week 3 ]
IL-6
- Biomarkers: interleukin 6 [ Time Frame: week 6 ]
IL-6
- Biomarkers: interleukin 6 [ Time Frame: week 12 ]
IL-6
- Biomarkers: interleukin 10 [ Time Frame: week 1 ]
IL-10
- Biomarkers: interleukin 10 [ Time Frame: week 3 ]
IL-10
- Biomarkers: interleukin 10 [ Time Frame: week 6 ]
IL-10
- Biomarkers: interleukin 10 [ Time Frame: week 12 ]
IL-10
- Biomarkers: tumor necrosis factor-alpha [ Time Frame: week 1 ]
TNF-alpha
- Biomarkers: tumor necrosis factor-alpha [ Time Frame: week 3 ]
TNF-alpha
- Biomarkers: tumor necrosis factor-alpha [ Time Frame: week 6 ]
TNF-alpha
- Biomarkers: tumor necrosis factor-alpha [ Time Frame: week 12 ]
TNF-alpha
- Biomarkers: high-sensitivity C-reactive Protein [ Time Frame: week 1 ]
hs-CRP
- Biomarkers: high-sensitivity C-reactive Protein [ Time Frame: week 3 ]
hs-CRP
- Biomarkers: high-sensitivity C-reactive Protein [ Time Frame: week 6 ]
hs-CRP
- Biomarkers: high-sensitivity C-reactive Protein [ Time Frame: week 12 ]
hs-CRP
- Biomarkers: soluble intercellular adhesion molecule-1 [ Time Frame: week 1 ]
sICAM-1
- Biomarkers: soluble intercellular adhesion molecule-1 [ Time Frame: week 3 ]
sICAM-1
- Biomarkers: soluble intercellular adhesion molecule-1 [ Time Frame: week 6 ]
sICAM-1
- Biomarkers: soluble intercellular adhesion molecule-1 [ Time Frame: week 12 ]
sICAM-1
- Biomarkers: tryptophan [ Time Frame: week 1 ]
tryptophan
- Biomarkers: tryptophan [ Time Frame: week 3 ]
tryptophan
- Biomarkers: tryptophan [ Time Frame: week 6 ]
tryptophan
- Biomarkers: tryptophan [ Time Frame: week 12 ]
tryptophan
- Biomarkers: kynurenine [ Time Frame: week 1 ]
kynurenine
- Biomarkers: kynurenine [ Time Frame: week 3 ]
kynurenine
- Biomarkers: kynurenine [ Time Frame: week 6 ]
kynurenine
- Biomarkers: kynurenine [ Time Frame: week 12 ]
kynurenine
- Biomarkers: neopterin [ Time Frame: week 1 ]
neopterin
- Biomarkers: neopterin [ Time Frame: week 3 ]
neopterin
- Biomarkers: neopterin [ Time Frame: week 6 ]
neopterin
- Biomarkers: neopterin [ Time Frame: week 12 ]
neopterin
- Adverse Events [ Time Frame: week 1 ]
Number of patients with adverse events, total number and type of adverse events
- Adverse Events [ Time Frame: week 3 ]
Number of patients with adverse events, total number and type of adverse events
- Adverse Events [ Time Frame: week 6 ]
Number of patients with adverse events, total number and type of adverse events
- Adverse Events [ Time Frame: week 12 ]
Number of patients with adverse events, total number and type of adverse events
|
Same as current
|
Treatment Expectations [ Time Frame: week -1 ] Treatment Credibility Scale (TCS)
|
|
|
Whole-body Hyperthermia for Moderate to Severe Depressive Disorder
|
Whole-body Hyperthermia for Moderate to Severe Depressive Disorder - a Randomized Controlled Tiral
|
The primary aim of this study is to investigate the effectiveness of whole-body hyperthermia in addition to standard medical care in comparison to standard medical care alone on depressive symptom severity in patients with moderate to severe depressive disorder.
Secondary aims included further quality of life outcomes, immunological parameters, and tolerability/safety of the hyperthermia.
|
Not Provided
|
Interventional
|
Not Applicable
|
Allocation: Randomized Intervention Model: Parallel Assignment Masking: Double (Investigator, Outcomes Assessor) Primary Purpose: Treatment
|
Depression, Unipolar
|
- Combination Product: Whole-body hyperthermia + standard medical care
Whole-body hyperthermia will be applied two times during 4 weeks (week 0 and 2 after randomization) in addition to standard medical care. The hyperthermia will be applied using Heckel-HT3000 MPIIb. During the 6 weeks of primary observation, the current medication should be maintained. The dose may be optimized with respect to clinical effectiveness and the reduction of side effects. The type of medication should not be changed during the 6 weeks. The use of additional somatic therapies such as sleep deprivation, light therapy, electroconvulsive therapy, or transcranial magnetic stimulation is not allowed.
- Combination Product: Standard medical care
Standard medical care included guideline-based anti-depressive drug treatment in combination with psychotherapy. During the 6 weeks of primary observation, the current medication should be maintained. The dose may be optimized with respect to clinical effectiveness and the reduction of side effects. The type of medication should not be changed during the 6 weeks. The use of additional somatic therapies such as sleep deprivation, light therapy, electroconvulsive therapy, or transcranial magnetic stimulation is not allowed.
|
- Experimental: Whole-body hyperthermia + standard medical care
Whole-body hyperthermia will be applied 2 times during 4 weeks in addition to guideline-based standard medical care for depression (anti-depressive drug treatment in combination with psychotherapy). At week 6, the primary outcome will be assessed. The participants will be reassessed 12 weeks after the start of the treatment with whole-body hyperthermia.
Intervention: Combination Product: Whole-body hyperthermia + standard medical care
- Active Comparator: Standard medical care
Participants will maintain standard medical care for depression (anti-depressive drug treatment in combination with psychotherapy). At week 6, the primary outcome will be assessed. The participants will be reassessed 12 weeks after randomization.
Intervention: Combination Product: Standard medical care
|
Not Provided
|
|
Recruiting
|
46
|
Same as current
|
June 2023
|
December 2022 (Final data collection date for primary outcome measure)
|
Inclusion Criteria:
- Unipolar depression (diagnosed according to the DSM-IV)
- Moderate depression: 17-23 points on the HAMD-17 or severe depression: ≥24 points on the HAMD-17
Exclusion Criteria:
- Participants who did not respond to prior antidepressant drug treatment, electroconvulsive therapy, or sleep deprivation (therapy-resistant depression)
- Acute suicidality
- Prior treatment with whole-body hyperthermia
- Contraindications to hyperthermia treatment: acute or feverish infections, severe cardiovascular diseases (e.g. angina pectoris, heart failure, thrombosis, bleeding diathesis), severe gastrointestinal diseases (e.g. renal insufficiency, hepatitis, liver cirrhosis, peptic ulcer), severe neurological diseases (e.g. epilepsy, multiple sclerosis, cerebrovascular malformations or brain tumors), severe endocrine diseases (e.g. hyperthyroidism), or oncological diseases without remission
- Participants taking anti-inflammatory or immunosuppressive drugs
- Participants with severe psychiatric comorbidities (e.g. schizophrenia, schizoaffective disorder, bipolar disorder, dementia, ADHD, obsessive-compulsive disorder, PTSD, alcohol or drug addiction)
- Women during pregnancy and breastfeeding
- Lack of ability to consent
|
Sexes Eligible for Study: |
All |
|
18 Years to 65 Years (Adult, Older Adult)
|
No
|
|
Germany
|
|
|
NCT03906149
|
18-8440-BO
|
No
|
Studies a U.S. FDA-regulated Drug Product: |
No |
Studies a U.S. FDA-regulated Device Product: |
No |
|
|
Holger Cramer, Universität Duisburg-Essen
|
Same as current
|
Universität Duisburg-Essen
|
Same as current
|
Not Provided
|
Study Director: |
Gustav Dobos, Prof. MD |
Center for Integrative Medicine and Health, University Hospital Essen, University of Duisburg-Essen |
|
Universität Duisburg-Essen
|
December 2022
|